Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
In the Spotlight

Seeking Synergy of Checkpoint Blockade through TGFβ Inhibition

Ellen Puré
Ellen Puré
Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ellen Puré
  • For correspondence: epure@upenn.edu
DOI: 10.1158/2326-6066.CIR-18-0784 Published December 2018
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Immunotherapy, including checkpoint blockade, is revolutionizing the treatment of cancers, but efficacy has, however, been limited to a subset of patients and can be of limited duration due to primary and acquired resistance to treatment. An article in this issue shows that inhibiting TGFβ can overcome resistance to blockade of one immune checkpoint, but not another, unless one follows where the mechanism leads.

See article by Zhao et al., p. 1459.

The capacity of the immune system to recognize and mount an initially effective response against immunogenic tumors is well established. Melanomas, although immunogenic with readily detectable tumor-associated antigen–reactive lymphocytes, often progress, due to tumor cell escape from immunity.

Self-limiting mechanisms have evolved to protect against overly robust and protracted immune responses. These include checkpoints such as CTLA-4 and PD-1 that, when engaged by their ligands (CD80/CD86 and PD-L1, respectively), act as brakes on T cell–mediated immunity. Although efficacious for some patients, most patients treated with anti–CTLA-4 and anti–PD1/PD-L1 exhibit resistance to checkpoint blockade. Anti–CTLA-4 and anti–PD-1/PD-L1 work through distinct mechanisms, however, and their combined use nearly doubles the response rate. To move into the clinic with any combination of immunotherapies with other modalities requires prioritization that is built upon scientific rationales and fundamental mechanistic insights.

TGFβ plays multiple protumoral roles such as suppressing CD8+ T cell activity while driving regulatory T cell (Treg) differentiation. TGFβ also enhances the generation of tumor-associated fibroblasts (TAFs), which form a physical barrier that can exclude T cells from tumors. Subsets of TAFs also produce immunosuppressive factors. The abundance of TAFs in melanoma correlates with resistance to checkpoint inhibitors (1, 2), providing the rationale for the studies from Zhao and colleagues in this issue (3). Small molecule inhibitors of TGFβ type I receptors were utilized to investigate stromal fibroblast-dependent effects of inhibition of TGFβ signaling and their impact on the efficacy of checkpoint inhibition, in an autochthonous PTEN−/− oncogenic BRAFV600E-driven murine model of melanoma.

As hypothesized, inhibition of TGFβ signaling enhanced efficacy of anti–CTLA-4, correlating with an increase in CD8+ cells and an increased ratio of CD8+ T cells to Tregs, suggesting reduced competition from Treg CTLA-4 for binding of effector T-cell CD28 to CD80 and CD86.

In contrast, inhibition of TGFβ signaling conferred resistance to anti–PD-1 by increasing fibroblast-derived MMP-9 cleavage of PD-L1 from melanoma cells, suppressing PD-1/PD-L1 signaling while conferring resistance to anti–PD-1. Cleavage of PD-L1 might be expected to enhance tumor growth if the tumors in the models used are immunogenic; however, the concomitant expansion of fibroblasts that exert multiple immunosuppressive functions might explain why this was not the case. Silencing fibroblast MMP-9 overcame resistance to anti–PD-1 and correlated with an enhanced ratio of CD8+ cells to Tregs. Thus, fibroblast-derived MMP-9 may be important in regulation of PD-L1 expression in melanoma and thereby, in turn, play a role in determining sensitivity versus resistance to anti–PD-1/PD-L1 therapy.

At first glance, these results appear to negate the concept that inhibition of TGFβ signaling might enhance efficacy of PD-1/PD-L1 checkpoint blockade. However, additional studies revealed that although initially responsive, melanomas in BRAFV600EPTEN−/− mice uniformly acquire resistance to anti–PD-1 alone. As resistance was associated with expansion of stromal fibroblasts and TGFβ signaling, they revisited the potential for synergy using a protocol in which TGFβ inhibition was delayed until emergence of anti–PD-1 resistance. This resulted in more effective antitumor immunity, resurrecting the therapeutic potential of this combination while highlighting the need for a mechanism-driven rational design of dosing regimens for combination therapies. These data also highlight the potential benefit of targeting TAFs to indirectly boost anti-tumor immunity and of taking indirect mechanisms into consideration when interpreting the impact of interventions designed to directly regulate anti-tumor immunity.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

  • ©2018 American Association for Cancer Research.

References

  1. 1.↵
    1. Tirosh I,
    2. Izar B,
    3. Prakadan SM,
    4. Wadsworth MH 2nd.,
    5. Treacy D,
    6. Trombetta JJ,
    7. et al.
    Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016;352:189–96.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Hugo W,
    2. Zaretsky JM,
    3. Sun L,
    4. Song C,
    5. Moreno BH,
    6. Hu-Lieskovan S,
    7. et al.
    Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016;165:35–44.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Zhao F,
    2. Evans K,
    3. Xiao C,
    4. DeVito N,
    5. Theivanthiran B,
    6. Holtzhausen A,
    7. et al.
    Stromal fibroblasts mediate anti–PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma. Cancer Immunol Res 2018;6:1459–71.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Cancer Immunology Research: 6 (12)
December 2018
Volume 6, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Seeking Synergy of Checkpoint Blockade through TGFβ Inhibition
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
Citation Tools
Seeking Synergy of Checkpoint Blockade through TGFβ Inhibition
Ellen Puré
Cancer Immunol Res December 1 2018 (6) (12) 1444; DOI: 10.1158/2326-6066.CIR-18-0784

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Seeking Synergy of Checkpoint Blockade through TGFβ Inhibition
Ellen Puré
Cancer Immunol Res December 1 2018 (6) (12) 1444; DOI: 10.1158/2326-6066.CIR-18-0784
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Location-Dependent B-cell Function in Glioblastoma
  • Of Microbes and Microsatellites
Show more In the Spotlight
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement